CRIS Current Research Information System

MARCHESINI REGGIANI, GIULIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.771
AS - Asia 17.855
EU - Europa 15.084
SA - Sud America 1.150
AF - Africa 940
Continente sconosciuto - Info sul continente non disponibili 790
OC - Oceania 27
Totale 59.617
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.428
VN - Vietnam 4.922
SG - Singapore 4.785
CN - Cina 4.105
GB - Regno Unito 3.842
IT - Italia 3.086
DE - Germania 1.932
HK - Hong Kong 1.252
SE - Svezia 1.186
FR - Francia 1.136
UA - Ucraina 1.001
IN - India 941
BR - Brasile 851
RU - Federazione Russa 828
IE - Irlanda 542
JP - Giappone 342
ZA - Sudafrica 340
NL - Olanda 328
BD - Bangladesh 286
EE - Estonia 273
KR - Corea 264
FI - Finlandia 254
CA - Canada 176
BG - Bulgaria 151
CI - Costa d'Avorio 145
TG - Togo 130
SC - Seychelles 126
AR - Argentina 120
PH - Filippine 114
ID - Indonesia 103
TR - Turchia 93
IQ - Iraq 89
JO - Giordania 87
NG - Nigeria 83
TH - Thailandia 83
MX - Messico 78
BE - Belgio 74
CH - Svizzera 71
PK - Pakistan 65
ES - Italia 64
AT - Austria 60
PL - Polonia 60
EC - Ecuador 53
UZ - Uzbekistan 42
GR - Grecia 38
TW - Taiwan 38
IR - Iran 37
EG - Egitto 34
CL - Cile 33
MY - Malesia 32
RO - Romania 28
CZ - Repubblica Ceca 26
SA - Arabia Saudita 26
PY - Paraguay 25
AU - Australia 23
CO - Colombia 22
LB - Libano 21
PE - Perù 19
JM - Giamaica 18
IL - Israele 17
MA - Marocco 16
LT - Lituania 15
HN - Honduras 14
KZ - Kazakistan 13
MD - Moldavia 13
OM - Oman 13
KE - Kenya 12
PT - Portogallo 12
SY - Repubblica araba siriana 12
TN - Tunisia 12
AE - Emirati Arabi Uniti 11
DK - Danimarca 11
HR - Croazia 11
NP - Nepal 11
DO - Repubblica Dominicana 10
UY - Uruguay 10
VE - Venezuela 10
AZ - Azerbaigian 9
CR - Costa Rica 8
AL - Albania 7
BO - Bolivia 7
DZ - Algeria 7
HU - Ungheria 7
PS - Palestinian Territory 7
YE - Yemen 7
ET - Etiopia 6
GT - Guatemala 6
LK - Sri Lanka 6
NO - Norvegia 6
SI - Slovenia 6
SK - Slovacchia (Repubblica Slovacca) 6
TT - Trinidad e Tobago 6
AO - Angola 5
MU - Mauritius 5
NI - Nicaragua 5
PA - Panama 5
A2 - ???statistics.table.value.countryCode.A2??? 4
GE - Georgia 4
PR - Porto Rico 4
SN - Senegal 4
Totale 58.771
Salva come PNG Salva come JPEG
Città #
Southend 3.329
Singapore 3.262
Fairfield 2.590
Ashburn 2.217
San Jose 1.339
Woodbridge 1.268
Hong Kong 1.196
Seattle 1.170
Santa Clara 1.161
Wilmington 1.106
Ho Chi Minh City 1.085
Houston 1.059
Chandler 1.052
Hanoi 976
Cambridge 914
Princeton 794
Dong Ket 678
Ann Arbor 674
Jacksonville 669
Council Bluffs 598
Hefei 556
Beijing 516
Boardman 500
Dublin 495
Lauterbourg 434
Bologna 358
Westminster 334
Nanjing 317
Los Angeles 311
Padova 303
Tokyo 303
Berlin 276
Helsinki 227
New York 220
Dallas 207
Buffalo 206
Seoul 202
Milan 194
Rome 185
Turin 171
Saint Petersburg 160
San Diego 158
Jinan 150
Shenyang 148
Sofia 148
Abidjan 145
Haiphong 141
Lomé 130
Da Nang 128
Frankfurt am Main 127
Mülheim 120
Redondo Beach 115
São Paulo 105
Hebei 97
Nanchang 96
Changsha 89
Guangzhou 87
Amman 85
Redmond 83
Tianjin 83
Abeokuta 82
Shanghai 82
Medford 80
Des Moines 76
Falls Church 74
The Dalles 73
Chicago 71
Brussels 70
Mahé 70
London 69
Verona 68
Zhengzhou 61
Johannesburg 60
Yubileyny 57
Ha Long 56
Phoenix 56
Bengaluru 53
Montreal 52
Biên Hòa 51
Dearborn 50
Hải Dương 50
Norwalk 50
Hangzhou 49
Jiaxing 49
Munich 48
Nuremberg 47
Thái Nguyên 46
Ningbo 45
Naples 44
Redwood City 44
Quận Bình Thạnh 43
Bremen 42
Falkenstein 42
Florence 41
Olalla 41
Toronto 41
Baghdad 40
Jakarta 40
Parma 39
Atlanta 38
Totale 38.037
Salva come PNG Salva come JPEG
Nome #
Il diabete con epatopatia 910
Quanto mangio veramente? 573
Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease 553
Sexuality and psychopathological aspects in premenopausal women with metabolic syndrome. 478
Prevalenza delle disfunzioni sessuali femminili nelle donne in menopausa con sindrome metabolica. 376
Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems 349
Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage 315
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial 301
An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers 281
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease 276
Predicting Frailty Condition in Elderly Using Multidimensional Socioclinical Databases 275
Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease. An overview 272
Does the liver accelerate ageing: Talking muscles and liver? 262
Prevalence of Sexual Dysfunction among Postmenopausal Women with and without Metabolic Syndrome. 256
NAFLD e cirrosi epatica 249
Switching among Equivalents in Chronic Cardiovascular Therapies: 'Real World' Data from Italy 247
A standard ballroom and Latin dance program to improve fitness and adherence to physical activity in individuals with type 2 diabetes and in obesity 243
Biomechanical and functional alterations in the diabetic foot: Differences between type I and type II Diabetes 241
Acute heart failure in the emergency department: a follow-up study 240
Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System 239
Double-heterozygous mutations involving both HNF1A (MODY3) and HNF4A (MODY1) genes: a case report 238
The Role of Medications for the Management of Patients with NAFLD 235
A controlled, class-based multicomponent intervention to promote healthy lifestyle and to reduce the burden of childhood obesity 234
Diabetes and NAFLD: a high-risk cohort with definite therapeutic potential 233
Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones: A Disproportionality Analysis of the US FDA Adverse Event Reporting System Database. 231
Association between Albumin Alterations and Renal Function in Patients with Type 2 Diabetes Mellitus 229
A randomized controlled trial of metformin vs. vitamin E or prescriptive diet in non-alcoholic fatty liver disease 229
Management of non-alcoholic fatty liver disease 226
Nonalcoholic fatty liver and insulin resistance: a cause-effect relationship? 222
Approcci nutrizionali nella steatoepatite non alcolica 222
Effects of cognitive-behavioral therapy on eating disorders: neurotransmitter secretory response to treatment 220
Correlation between DXA and laboratory parameters in normal weight, overweight, and obese patients 219
Non-alcoholic steatohepatitis in patients cared in metabolic units 216
Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage. 216
A physical activity program to reinforce weight maintenance following a bheavior program in overweight/obese subjects. 215
Cognitive-behavioral strategies to increase the adherence to exercise in the management of obesity 215
Long-term weight loss maintenance for obesity: A multidisciplinary approach 214
Psychological status and depression in patients with liver cirrhosis 213
Emotional intelligence, emotion regulation and affectivity in adults seeking treatment for obesity. 213
Comparison of WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes 210
Eating habits in patients affected by metabolic syndrome and liver disease (hepatitis, cirrhosis and liver transplant) 210
The metabolic syndrome in treatment-seeking obese persons 209
Massive weight loss without surgery in a super obese patient 208
Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy 207
A combined HPLC-immunoenzymatic comprehensive screening for suspected drug poisoning in the emergency department 206
Psychological profile and quality of life of morbid obese patients attending a cognitive behavioural program 206
Adiponectin isoforms, insulin resistance and liver histology in nonalcoholic fatty liver disease 206
The construct validity of the Short Form-36 health survey and its relationship with BMI in obese outpatients 205
Pathogenetic mechanisms and cardiovascular risk: Differences between HbA1c and oral glucose tolerance test for the diagnosis of glucose tolerance 205
Are behavioral approaches feasible and effective in type 2 diabetes? A propensity score analysis 204
Non-alcoholic fatty liver disease/Non-alcoholic steatohepatitis (NAFLD/NASH): treatment 203
Weight cycling in treatment-seeking obese persons. Data from the QUOVADIS study 203
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C 203
Long-term follow-up of web-based and group-based behavioural intervention in NAFLD in a real world clinical setting 202
Weight loss for a healthy liver 199
Cognitive-behavioral treatment of nonalcoholic fatty liver disease: a propensity score-adjusted observational study 198
A randomized trial of energy-restricted high-protein versus high-carbohydrate, low-fat diet in morbid obesity. 197
Supervised vs. self-selected physical activity for individuals with diabetes and obesity: the Lifestyle Gym program 194
Reply to: “Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients” 191
Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease? 191
Psychological distress in morbid obesity in relation to weight history 190
Behavioral aspects of nonalcoholic fatty liver disease: diet, causes, and treatment 190
Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting 189
Weight loss expectations in obese patients seeking treatment at medical centers 188
A position statement on NAFLD/NASH based on the EASL 2009 special conference 187
The association between emotional intelligence and weight loss after a psychoeducational intervention for obese patients. 187
Dual-Energy X-Ray Absorptiometry and Newest Technology: A Therapeutic Index for Different Treatment Programs in the Management of Obesity? 186
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease 186
Which treatment for nonalcoholic fatty liver disease? 185
Effects of cognitive-behavioral treatment for weight loss in the family members 184
A psychological support program for individuals with type 1 diabetes 184
Impaired Lipid Profile is a Risk Factor for the Development of Sexual Dysfunction in Women 184
Progetto "GULLIVER". Intervento nutrizionale via internet nella sindrome metabolica 183
Insulin glargine improves glycemic control and health-related quality of life in type 1 diabetes 183
Stress Hyperglycemia and Complications Following Traumatic Injuries in Individuals With/Without Diabetes: The Case of Orthopedic Surgery 183
Real-world prevalence of metabolic associated fatty liver disease (MAFLD) and fibrotic-non-alcoholic steatohepatitis (NASH) in patients with obesity (PwO) in an outpatient specialist clinic in Italy 182
Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes. 182
Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study 182
Lifestyle Intervention in NAFLD: Long-Term Diabetes Incidence in Subjects Treated by Web- and Group-Based Programs 180
Obesity-associated liver disease 180
Physical activity support or weight loss counseling for nonalcoholic fatty liver disease? 180
Lifestyle changes for the treatment of nonalcoholic fatty liver disease-a 2015-19 update 180
Dati preliminari sullo studio della sintomatologia ortoressica tra pazienti diabetici affetti da epatopatia. 180
Eating behavior affects quality of life in type 2 diabetes mellitus 178
Metabolic Syndrome and NASH 178
Trattamento dell’obesità: La lezione della storia 178
3D bone architecture in weight-bearing combined to pressure measurements in the diabetic foot 178
ESPEN Guidelines on Parenteral Nutrition: Hepatology 177
Steatosi epatica non alcolica e obesità 176
The management of severe hypoglycemia by the emergency system: The HYPOTHESIS study 176
DXA-assessed changes in body composition in obese women following two different weight loss programs 176
Dapagliflozin and cardiovascular outcomes: anything else to DECLARE? 176
Prospective validation of a proposal for diagnosis and management of patients attending the emergency department for mild head injury 175
Antiplatelet therapy and the outcome of subjects with intracranial injury: the Italian SIMEU study 175
A 360-degree overview of body composition in healthy people: Relationships among anthropometry, ultrasonography, and dual-energy x-ray absorptiometry 175
Metformin and the Liver: Unlocking the Full Therapeutic Potential 173
Update on nutritional supplementation with branched-chain amino acids 172
Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver 172
Metabolic syndrome in liver transplantation. Relation to etiology and immunosuppression 172
Vascular risk in young women with polycystic ovary and polycystic ovary syndrome 172
Totale 22.647
Salva come PNG Salva come JPEG
Categoria #
all - tutte 167.584
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 167.584
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20225.528 0 229 455 457 678 370 171 470 242 263 1.147 1.046
2022/20235.985 685 818 315 736 420 394 253 330 1.010 178 531 315
2023/20242.040 133 318 117 148 159 360 136 194 82 161 129 103
2024/20257.476 321 1.148 597 583 1.578 394 465 210 114 358 186 1.522
2025/202618.009 1.873 1.653 1.581 1.395 1.858 1.064 1.755 1.180 3.001 1.167 751 731
2026/20271.304 512 792 0 0 0 0 0 0 0 0 0 0
Totale 59.617